AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kenny, G. E.
Right arrow Articles by Huang, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kenny, G. E.
Right arrow Articles by Huang, W. M.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2493-2496, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Sparfloxacin Selects Gyrase Mutations in First-Step Mycoplasma hominis Mutants, whereas Ofloxacin Selects Topoisonmerase IV Mutations

George E. Kenny,1,* Patrick A. Young,1 Frank D. Cartwright,1 Karen E. Sjöström,1 and Wai M. Huang2

Department of Pathobiology, University of Washington, Seattle, Washington,1 and Division of Molecular Biology and Genetics, University of Utah, Salt Lake City, Utah2

Received 14 January 1999/Returned for modification 19 April 1999/Accepted 26 July 1999

The role of mutations in the genes for GyrA and ParC in quinolone resistance in Mycoplasma hominis was studied. Selection with sparfloxacin gave mutations at GyrA83 (Serright-arrowLeu; Escherichia coli numbering) or GyrA87 (Gluright-arrowLys), and mutants had increased levels of resistance to sparfloxacin (8- to 16-fold) but not to ofloxacin. Selection with ofloxacin gave changes at ParC80 (Serright-arrowIle) or ParC84 (Gluright-arrowLys), and mutants were four- to eightfold more resistant to ofloxacin but not to sparfloxacin. Selection of second-step mutants from strains with ParC mutations with either quinolone yielded double mutants with additional mutations at GyrA83 (Serright-arrowTrp or Serright-arrowLeu) or GyrA87 (Gluright-arrowLys). Second-step selection of GyrA mutants gave additional mutations at ParC80 (Serright-arrowIle) or ParC84 (Gluright-arrowLys). Two-step mutants showed high levels of resistance to ofloxacin (MICs, 64 to 128 µg/ml) and moderate levels of resistance to sparfloxacin (MICs, 2 to 8 µg/ml). The primary target of ofloxacin in first-step mutants of Mycoplasma hominis was ParC, whereas that for sparfloxacin was GyrA.

* Corresponding author. Mailing address: Department of Pathobiology, Box 357238, University of Washington, Seattle, WA 98195. Phone: (206) 543-1036. Fax: (206) 543-3873. E-mail: kennyg{at}u.washington.edu.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2493-2496, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.